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Importance of the field: Populations, the world over, age. Prevalence of
hypertension increases with advancing age. Despite the advances over the
past 30 years, there are still unresolved issues regarding antihypertensive
therapy in the elderly.
Areas covered in this review: The present review discusses the available
evidence supporting treatment of hypertension in the elderly.
What the reader will gain: In the 1980s and 1990s, a number of trials were
performed and proved that active treatment of hypertension in individuals
above the age of 60 -- 65 years, compared with placebo or no treatment,
reduces the risk of complications. In the 1990s, the same was proven in
patients specifically affected with isolated systolic hypertension, the predom-
inant form of hypertension in the elderly. The subsequent years witnessed the
publication of trials that showed that most antihypertensive drugs are capa-
ble of substantially reducing risk. Finally, treatment of hypertension in the
very elderly was proven to be beneficial.
Take home message: In spite of these advances, we still lack evidence
in elderly patients with mild isolated systolic hypertension and are therefore
in need of a properly designed, randomized, placebo-controlled trial.
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1. Aging of populations and blood-pressure-associated risk
Populations worldwide, especially those in Western and westernized countries, are
undergoing a profound demographic change as they age. As recently shown, 50%
of people who were born in recent years in countries such as the UK, USA, France,
Denmark or Japan will live to celebrate their hundredth birthday [1]. Population-
wise, blood pressure (BP) raises with advancing age, resulting in an age-related
increase in the prevalence of hypertension [2,3].
The pathophysiology of hypertension in the elderly differs from that implicated
in the disease at younger age. The major factor in the pathogenesis of hypertension
in the elderly is the progressive stiffening of large conduit arteries with subsequent
increase in pulse-wave velocity, resulting in an increase of systolic (SBP) and a
decrease of diastolic (DBP) blood pressure [4,5].
Increased SBP has been associated with increased rates of complications, some of
which tend to be closely related to pulse pressure. A 10-mmHg higher SBP has been
shown to be associated with a substantial increase of risk of major complications
such as all-cause mortality (14%), cardiovascular mortality (12%), fatal and non-
fatal cardiovascular events (8%) and stroke (12%) [6]. This risk has been shown to
be reversible upon effective antihypertensive treatment.
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2. Trials in elderly patients with
systolic-diastolic hypertension
Over the past three decades a number of trials have addressed
the issue of whether treatment of hypertension in the elderly
would be beneficial. The early trials included patients with
systolic and/or diastolic hypertension, and treatment decisions
were based primarily on DBP.
The Australian Therapeutic Trial in Mild Hypertension
(ATTMH) included 582 patients aged ‡ 60 (mean 64) years.
The patients were free from cardiovascular complications and
their DBP at baseline had to range from 95 to 109 mmHg
(mean blood pressure at baseline 167/101 mmHg). Patients
were randomized to receive active treatment based on
chlorothiazide 500 mg, with possibility of doubling the
dose, addition of methyldopa (250 -- 2000 mg), propranolol
(40 -- 320 mg) or pindolol (5 -- 30 mg), and clonidine
(150 -- 900 mg) or hydralazine (10 -- 200 mg), or to matching
placebos. After 3.9 years of follow-up (median), the compos-
ite end point of all-cause mortality and all cardiovascular and
renal complications was reduced (p < 0.025) in the active
treatment group by 39% [7].
The European Working Party on High Blood Pressure in
the Elderly (EWPHE) trial included 840 patients aged
60 (mean 72) years and more. The patients’ blood pressure
at entry had to be in the range of 160 -- 239 mmHg SBP
and 90 -- 119 mmHg DBP (mean blood pressure at baseline
183/101 mmHg). Patients were randomized to receive either
active treatment based on hydrochlorothiazide (25 mg)/triam-
terene (50 mg), with add-on methyldopa (250 -- 2000 mg) or
matching placebos. The actively treated patients, after mean
follow-up of 4.6 years, experienced 27% (p = 0.037) fewer
cardiovasular deaths but not deaths of any cause (9%
reduction, p = 0.41) [8].
The Hypertension in Elderly Patients in Primary Care
(HEP) trial included 884 patients aged 60 -- 79 (mean 69)
years with an SBP of ‡ 170 mmHg or DBP
of ‡ 105 mmHg (mean blood pressure at baseline
196/99 mmHg). Patients were randomly assigned to receive
active treatment based on atenolol (100 mg), bendrofluaside
(5 mg), a combination of the two with add-on methyldopa
(500 mg) or no treatment. After mean follow-up of 4.4 years,
there were 42% fewer strokes (p < 0.03) in the actively treated
group, the benefit that was mainly driven by a 70% reduction
of fatal stroke (p < 0.025). Neither the incidence of myocar-
dial infarction nor total mortality differed significantly
between the groups [9].
The Swedish Trial in Old Patients with Hypertension
(STOP1) included 1627 individuals aged between 70 and
84 (mean 76) years. To be included, the patients’ SBP had
to be between 180 and 230 mmHg with a DBP
of ‡ 90 mmHg; or DBP had to be between 105 and
120 mmHg irrespective of SBP (mean blood pressure at base-
line 195/102 mmHg). Patients were randomly assigned to
receive either active treatment, based on atenolol (50 mg),
metoprolol (100 mg), pindolol (5 mg) or hydrochlorothiazide
(25 mg)/amiloride (2.5 mg), or matching placebos. The
actively treated patients experienced 40% (p = 0.0031) fewer
strokes, myocardial infarctions and other cardiovascular
deaths combined, with 47% (p = 0.0081) fewer strokes,
76% fewer fatal strokes and 70% fewer cardiovascular deaths.
Total mortality was reduced by 43% (p = 0.0079) [10].
In the Medical Research Council trial of treatment of
hypertension in older adults (MRC2), 4396 patients
aged between 65 and 74 (mean 70) years, whose SBP was
160 -- 209 mmHg and DBP < 115 mmHg (mean blood
pressure at baseline 185/91 mmHg), were randomized to
active treatment based on a diuretic (hydrochlorothiazide
25 -- 50 mg/amiloride 2.5 -- 5 mg) or a beta-blocker (atenolol
50 -- 100 mg) with add-on nifedipine (20 mg) and two
matching placebo groups. The combined analysis showed
that actively treated patients, after 5.8 years of follow-up,
had 25% (p = 0.04) fewer strokes and 17% (p = 0.03) fewer
cardiovascular complications.
Subgroup analysis revealed the effect to be driven by the
group treated with diuretic and absent in the group that
received atenolol; it was observed mostly in nonsmoking
patients (Table 1) [11].
3. Trials in elderly patients with isolated
systolic hypertension
Three large-scale trials addressed the issue of treatment of iso-
lated systolic hypertension (ISH) in the elderly. The Systolic
Hypertension in the Elderly Program (SHEP) included
4763 patients aged ‡ 60 (mean 72) years with SBP
of ‡ 160 mmHg and DBP of < 90 mmHg (mean blood
pressure at baseline 170/77 mmHg). Over the mean follow-
up of 4.5 years, the chlorthalidone (12.5 -- 25 mg, with
add-on atenolol 25 mg and reserpine 0.05 mg)-based therapy,
compared with placebo, reduced the incidence of stroke by
36% (p < 0.0003) and fatal and nonfatal cardiovascular events
by 32% (95% CI, 20 -- 44%); however, total mortality did
not differ between the randomization groups [12].
Article highlights.
. Hypertension is the most important modifiable
cardiovascular risk factor.
. Treatment of hypertension in the elderly in general
is beneficial.
. Prevention of cardiovascular complications upon
treatment of hypertension is due to blood-pressure
lowering rather than specific drug properties.
. We are in need of a randomized, placebo-controlled
clinical trial to answer the question whether treatment
of mild uncomplicated isolated systolic hypertension in
the elderly is beneficial.
This box summarizes key points contained in the article.
Hypertension in the elderly
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The Systolic Hypertension in Europe (Syst-Eur) trial
included 4695 elderly patients with ISH (mean age 70 years;
mean blood pressure at baseline 174/86 mmHg). Active
treatment based on nitrendipine (10 -- 40 mg) with
add-on enalapril (5 -- 20 mg) and hydrochlorothiazide
(12.5 -- 25 mg), compared with matching placebos, reduced
the incidence of fatal and nonfatal stroke by 42%
(p < 0.003), and fatal and nonfatal cardiovascular events com-
bined by 31% (p < 0.001), with a borderline trend towards a
reduction in cardiovascular mortality by 27% (p = 0.07) [13].
The effect of treatment was especially pronounced in patients
with diabetes mellitus. This has been the only trial so far to
show clear-cut, 50% (p = 0.05) reduction in the incidence of
dementia associated with active treatment of hypertension [14].
Finally, the Systolic Hypertension in China (Syst-China)
trial confirmed the findings of both SHEP and Syst-Eur in
2394 Chinese elderly patients with ISH [15].
In 2000, Staessen et al. carried out a quantitative overview
of ISH in the elderly based on large randomized trials that
emerged in the 1980s and 1990s [6]. This meta-analysis
incorporated the SHEP, Syst-Eur and the Syst-China
trials, involving exclusively elderly patients with ISH (SBP
160 mmHg or higher), and also the EWPHE, HEP,
STOP1 and MRC1 trials, which included subgroups of
elderly patients with ISH, and the MRC2 trial, which
involved older adults. This paper, based thus on eight trials
(15,693 patients; mean age ranged 62 -- 76 years), showed
that active treatment in elderly patients with ISH compared
with placebo or no treatment reduced total mortality
by 13% (p = 0.02), cardiovascular mortality by 18%
(p = 0.01), stroke events by 30% (p < 0.0001) and coronary
events by 23% (p = 0.002), and all cardiovascular events by
25% (p < 0.0001) [6]. Therefore, these landmark clinical trials
provide convincing support for the routine treatment of ISH
in elderly patients (Table 1).
4. Trials testing newer drug classes in
elderly patients
Following the encouraging findings of the early trials in treat-
ing systolic hypertension in older subjects, many new trials
have focused on elucidating the effects of angiotensin-
converting enzyme (ACE) inhibitors, angiotensin-receptor
blockers (ARBs), calcium channel blockers (CCBs) and
other blood-pressure-lowering drugs on mortality and major
cardiovascular morbidity (Table 1) [16-20].
The Second Australian National Blood Pressure Study
(ANBP2) included 6083 patients aged 65 -- 84 years with
mild to moderate hypertension (mean age 71.9 years; mean
blood pressure 168/91 mmHg) [16]. Patients were randomized
to receive active treatment based on enalapril or hydrochloro-
thiazide, with possible addition of beta-blockers or CCBs.
After median follow-up of 4.1 years, patients treated with
the enalapril-based regimen had an 11% lower rate of primary
composite end point (all-cause mortality and cardiovascular
events combined). However, the effect was driven by a 17%
between-group difference observed in men, but not
women [16].
The Study of Cognition and Prognosis in the Elderly
(SCOPE), a prospective, double-blind, randomized, parallel-
group study, examined the effects of the ARB candesartan
on cardiovascular events, stroke and cognition in 4964 elderly
patients with mild hypertension (mean age 76.4 years; mean
blood pressure 166.3/90.3 mmHg) [17]. After a mean
follow-up of 3.7 years, the ARB-based treatment reduced
nonfatal stroke by 27.8% and fatal and nonfatal stroke by
23.6%. There were no significant differences in myocardial
infarction and cardiovascular mortality, and cognitive
function was well maintained in both the active treatment
and placebo groups.
The Losartan Intervention for Endpoint Reduction (LIFE)
trial was a randomized, double-blind study that examined
the effects of the ARB losartan on cardiovascular mortality,
stroke and myocardial infarction [18]. In a subgroup analysis
of the trial, the LIFE-ISH, 1326 elderly patients with
isolated hypertension (mean age 70.3 years; mean blood pres-
sure 174/83 mmHg) and left ventricular hypertrophy received
once-daily losartan (50 -- 100 mg) or atenolol (50 -- 100 mg)
(with hydrochlorothiazide 12.5 -- 25 mg, as the second
agent in both arms) for a mean of 4.7 years. The compo-
site end point of cardiovascular death, stroke or myocardial
infarction was reduced by 25% (p = 0.02) with losartan
compared with atenolol.
The Systolic Hypertension in the Elderly Long-term
Lacidipine (SHELL) study compared the effect of lacidipine
(4 -- 6 mg) and chlorthalidone (12.5 -- 25 mg) in 1882 elderly
patients with ISH (age ‡ 60 years; mean blood pressure
178/87 mmHg) followed for 32 months [19]. Both drugs
markedly reduced SBP and the overall incidence of the pri-
mary end point, a composite of cardiovascular and cerebro-
vascular events, was 9.3% in both groups. The International
Nifedipine GITS Study: Intervention as a Goal in Hyperten-
sion Treatment (INSIGHT) study included 6321 patients
aged 55 -- 80 years with hypertension and at least one addi-
tional cardiovascular risk factor. Although not a selective
ISH trial, INSIGHT contained a subgroup of 1498 patients
with ISH (mean blood pressure 173/88 mmHg) that was ana-
lyzed separately (INSIGHT-ISH) [20]. In the subgroup analy-
sis, the CCB nifedipine GITS (30 -- 60 mg) was compared
with the diuretic combination hydrochlorothiazide/amiloride
(25/2.5 -- 50/5 mg), with add-on enalapril (5 -- 10 mg), and
it evaluated a composite end point of death due to cardio-
vascular and cerebrovascular causes and nonfatal stroke,
myocardial infarction and heart failure. Both treatments
had similar effects on blood-pressure lowering and on the
primary outcome (6.0% with nifedipine, 6.6% with
hydrochlorothiazide/amiloride).
Several short-term studies compared the blood-pressure-
lowering effects and safety of ARBs and CCBs in elderly
patients with ISH. Valsartan and Amlodipine for the
Hypertension in the elderly
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Treatment of Isolated Systolic Hypertension in the Elderly
(Val-Syst), a 24-week randomized, double-blind study,
compared the risk/benefit profiles of the ARB valsartan with
the CCB amlodipine in 421 elderly (aged 60 -- 80 years)
patients with ISH [21]. The results showed that valsartan, given
alone or in combination with hydrochlorothiazide, showed
similar efficacy but better tolerability than amlodipine-based
treatment. Another randomized, double-blind, placebo-
controlled, 12-week study compared the effects of the diuretic
indapamide with the ARB candesartan and the CCB amlodi-
pine in 1758 patients (aged 40 -- 80 years) with hyperten-
sion [22]. In a subgroup of patients with ISH (n = 388, mean
age 64 years), the three treatments significantly reduced
SBP; though indapamide did not change DBP and, thus,
reduced pulse pressure significantly.
The findings from these recent clinical trials demonstrate
that blockade of the renin-angiotensin system at various
points in the cascade are effective blood-pressure-lowering
medications. Studies comparing ARBs with other regimens
showed a lower incidence of stroke, but not of other cardio-
vascular outcomes, with renin-angiotensin-directed regimens,
and equivalence of non-renin-angiotensin treatments in
reducing events (CCBs, diuretics) based on degree of blood
pressure lowering.
Encouraging results have recently been reported with aliski-
ren, the first representative of a new class of nonpeptide, orally
active renin inhibitors. The AGELESS trial (Aliskiren for
Geriatric Lowering of Systolic Hypertension), compared the
efficacy of aliskiren with ramipril in systolic hypertension
(SBP ‡ 140 mmHg) in patients aged ‡ 65 years and demon-
strated that aliskiren had superior potency for lowering SBP
and DBP, provided greater attainment of blood pressure
goal and required less add-on therapy compared with ramipril
in elderly patients with systolic hypertension [23]. This was a
36-week, randomized, double-blind, parallel-group, active-
controlled, optional-titration study of 901 elderly patients
(aliskiren, n = 457; ramipril, n = 444). Decreases from base-
line mean sitting SBP and mean sitting DBP with aliskiren
monotherapy (-14.0 and -5.1 mmHg, respectively) were non-
inferior (p < 0.001 for both values) and superior to ramipril
monotherapy (-11.6, -3.6 mmHg; p = 0.02, p < 0.01, respec-
tively). However, data on long-term mortality and morbidity
are needed.
5. Treatment of hypertension in the
very elderly
Until recently, the best available data on hypertensive people
aged > 80 years came from the Individual Data Analysis of
Antihypertensive Drug Intervention Trials (INDANA) group.
This database included 1670 patients above 80 years of age
who were randomized in seven clinical trials that compared
active drug therapy versus placebo or no treatment [24]. Octo-
genarians (mean age 83 years) comprised only 13% of the
overall population in these trials. In this meta-analysis, active
drug therapy significantly reduced fatal and nonfatal strokes
by 34% and major cardiovascular events by 22%; but mortal-
ity and cardiovascular death rates were higher, by 6 and 1%,
respectively -- though these increases were not statistically
significant. However, the Hypertension in the Very Elderly
Trial (HYVET; 3845 patients, aged ‡ 80 years) has proved
that it is not too late to start antihypertensive therapy in older
people [25]. In short, the active treatment based on indapa-
mide sustained-release (1.5 mg) with add-on perindopril
(2 -- 4 mg) produced significant reductions in the risk of death
from any cause by 21% (p = 0.02), fatal stroke by 39%
(p = 0.05), and incident heart failure by 64% (p < 0.001),
with borderline significant reductions in incidence of fatal
and nonfatal stroke by 30% (p = 0.06) and cardiovascular
mortality by 23% (p = 0.06). This publication expands the
upper limit of the age spectrum for which there is evidence
from clinical trials of a treatment benefit (Table 1) [24,25].
6. Message reinforced
In a very recent meta-analysis, Musini et al. identified 15 trials
of at least 1 year’s duration (24,055 patients) of hypertension
in the elderly (SBP ‡ 140 mmHg and/or DBP ‡ 90 mmHg)
including the HYVET trial [26]. These trials mostly evalua-
ted first-line thiazide diuretic therapy for a mean duration
of treatment of 4.5 years versus placebo or no treatment.
The authors showed that treatment reduced total morta-
lity (response rate (RR) = 0.90, confidence interval (CI)
0.84 -- 0.97) and total cardiovascular morbidity and mortality
(RR = 0.72, CI 0.68 -- 0.77) owing to reduction in both cere-
brovascular as well as coronary heart disease mortality and
morbidity. They confirmed similar results in the three trials
restricted to persons with ISH (RR = 0.68, CI 0.61 -- 0.75).
In very elderly patients (‡ 80 years old), treatment reduced
total cardiovascular mortality and morbidity (RR = 0.75, CI
0.65 -- 0.87) only, owing to cerebrovascular mortality and
morbidity (RR = 0.66, CI 0.52 -- 0.83), whereas no reduction
in total mortality was observed (RR = 0.98, CI 0.87 -- 1.10).
The authors have also drawn attention to the withdrawals
due to adverse effects that were associated with treatment
(RR = 1.71, CI 1.45 -- 2.00). However, the patients inclu-
ded in HYVET were relatively healthy and a low proportion
had experienced cardiovascular complications before
inclusion [26].
7. Choice of regimen
Most elderly patients with hypertension will need more than
one drug for blood pressure control. Combining antihyper-
tensive drugs with complementary mechanisms of action has
many benefits, including greater antihypertensive efficacy
and lower rates of dose-related adverse events, because lower
doses of the individual components than would be used in
monotherapy can be administered. The use of fixed-dose
combination pills may also lower overall cost and improve
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medication adherence in elderly individuals with hyperten-
sion. The guidelines encourage the use of diuretics, both as
first-line treatment and in combination with other drugs.
The choice of a second agent or a first-line drug, if a patient
cannot take thiazide-type diuretics, depends on specific com-
pelling indications. In elderly patients with moderate ISH,
a diuretic or long-acting dihydropiridine CCB is recom-
mended for initiation of therapy, largely based on the results
from SHEP, Syst-Eur and Syst-China [12,13,15]. On the other
hand, data from the Avoiding Cardiovascular Complications
in Patients Living with Isolated Systolic Hypertension
(ACCOMPLISH) trial, seem to indicate that the ACE
inhibitor plus CCB combination is better than ACE-
inhibitor plus diuretic. However, the ACCOMPLISH trial
has been criticized because it used low-dose hydrochlorothi-
azide in the ACE inhibitor plus diuretic arm [27]. Chlortha-
lidone, used in the Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack (ALLHAT) trial [28]
and other National Heart, Lung, and Blood Institute-
sponsored trials, has a longer duration of action than hydro-
chlorothiazide, and it is more effective in lowering blood
pressure. In the Multiple Risk Factor Intervention Trial
(MRFIT), hydrochlorothiazide was associated with an
unfavorable trend in mortality, and hence the protocol was
amended after about 5 years of randomization, and chlortha-
lidone was used in place of hydrochlorothiazide, which
seems to have caused a more favorable mortality trend [29].
The CCBs are metabolically neutral as they do not induce
the metabolic side effects common on thiazide diuretics.
In a meta-analysis in which 9 of 13 trials involved hyperten-
sives older than 60 years, CCBs have been found to decrease
the risk of stroke more effectively than other antihyper-
tensive agents [30]. A meta-analysis by the Blood Pressure
Lowering Treatment Trialists’ Collaboration analyzed
results of 31 trials that compared an ACE inhibitor or a
CCB versus placebo or compared different antihypertensive
drug regimens (ACE inhibitor vs diuretic or beta-blocker,
CCB vs diuretic or beta-blocker, and ACE inhibitor vs
CCB) [31]. The study outcomes included total major
cardiovascular events (fatal and nonfatal stroke, nonfatal
myocardial infarction or death from coronary heart disease,
or heart failure) and compared the effects on the primary
outcome between the < 65-year-old and ‡ 65-year-old age
groups. The analysis did not show substantial age-related
difference in the effect of treatment, which included
diuretics or beta-blockers, CCBs and ACE inhibitors;
hence, the beneficial effects were attributed primarily to
blood pressure reduction achieved rather than the choice of
drug [31].
8. Compliance
The treatment of hypertension in the elderly presents many
challenges. Elderly persons with hypertension usually take
several medications for a variety of concomitant conditions,
mostly chronic, and this makes them more likely to misman-
age their antihypertensive medications. Many medications
frequently taken by elderly patients, such as NSAIDs, inter-
fere with the actions of antihypertensive medications. Addi-
tionally, orthostatic hypotension, a condition common in
the elderly, may be aggravated by antihypertensive treat-
ment [32]. High blood pressure also exacerbates aging-related
cognitive decline and may predispose to the development
of dementia in the elderly [33]. The higher incidence of
cognitive and memory impairment in the elderly necessitates
the use of simple antihypertensive regimens to improve
medication adherence and blood pressure control.
9. Future directions and expert opinion
Treatment of hypertension in elderly patients is, largely,
beneficial. It reduces health burden to the society while
decreasing the suffering of affected individuals and their
families. However, the evidence we have at present does
not apply equally to all our elderly hypertensive patients. It
is widely accepted that the relationship between level of
blood pressure and cardiovascular risk is linear and universal
across age groups [34]. On the other hand, some data point to
the possibility that in older individuals the SBP cut-off value
for increase in cardiovascular risk is 160 mmHg rather than
140 mmHg (Figure 1) [35]. Similarly, no trial in elderly
hypertensives has included patients with mild ISH with
SBP in the range of 140 -- 150 mmHg, marking a lack of
trial evidence for the guideline recommendation to lower
SBP in such individuals to < 140 mmHg -- an issue recently
appreciated in the guideline reappraisal document [36,37]
(Figure 2). The only trial so far that has tested the hypothesis
that more stringent (goal SBP < 140 mmHg) blood pressure
control in elderly patients would be beneficial, the JATOS
(Japanese trial to assess optimal systolic blood pressure in
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Figure 1. Relation between systolic blood pressure and risk
of death.
The cut-off is age- and sex-dependent. Reanalysis of data from Framingham
Heart Study. Reproduced with permission from [35].
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elderly hypertensive patients) trial, yielded negative
results [38]; and some data point to the possibility of a
J-shaped relation between blood pressure and cardiovascular
complications, especially in older patients with clinically
more advanced atherosclerosis or with diabetes mellitus [39].
Both issues can and should be resolved to avoid unnecessary
treatment or to avoid unnecessary cerebrovascular and
cardiovascular morbidity and mortality. We clearly need a
placebo-controlled clinical trial to guide us in what seems
to be one of the last terrae incognitae of antihypertensive
therapy in the elderly.
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Figure 2. Goal blood pressure and overall result of a trial.
EW: EWPHE (European Working Party on High Blood Pressure in the Elderly trial); CW: HEP (Hypertension in Elderly Patients in Primary Care trial);
MRC: MRC2 (Medical Research Council trial of treatment of hypertension in older adults); S. Eur: Syst-Eur (Systolic Hypertension in Europe trial);
S. Ch: Syst-China (Systolic Hypertension in China trial); SCOPE: Study of Cognition and Prognosis in the Elderly; SHEP: Systolic Hypertension in the Elderly Program;
STOP: Swedish Trial in Old Patients with Hypertension; HYVET: Hypertension in the Very Elderly Trial; JATOS: Japanese trial to assess optimal systolic blood pressure
in elderly hypertensive patients.
Benefit was observed in all trials except SCOPE (partial benefit -- hatched bar) and JATOS (no benefit -- dark grey bar). Reproduced with permission from [37].
Ga˛sowski, Tikhonoff, Stolarz-Skrzypek, Thijs, Grodzicki, Kawecka-Jaszcz & Staessen
Expert Opin. Pharmacother. (2010) 11(Suppl.1) S7
Ex
pe
rt 
O
pi
n.
 P
ha
rm
ac
ot
he
r. 
D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
19
5.
15
0.
23
2.
34
 o
n 
05
/1
7/
10
Fo
r p
er
so
na
l u
se
 o
nl
y.
Bibliography
1. Christensen K, Doblhammer G, Rau R,
Vaupel JW. Ageing populations: the
challenges ahead. Lancet
2009;374:1196-208
2. Burt VL, Whelton P, Roccella EJ, et al.
Prevalence of hypertension in the US
adult population. Results from the Third
National Health and Nutrition
Examination Survey, 1988 -- 1991.
Hypertension 1995;25:305-13
3. Kearney PM, Whelton M, Reynolds K,
et al. Global burden of hypertension:
analysis of worldwide data. Lancet
2005;365:217-23
4. Laurent S, Boutouyrie P, Benetos A.
Pathophysiology of hypertension in the
elderly. Am J Geriatr Cardiol
2002;11:34-9
5. Kocemba J, Kawecka-Jaszcz K,
Gryglewska B, Grodzicki T. Isolated
systolic hypertension: pathophysiology,
consequences and therapeutic benefits.
J Hum Hypertens 1998;12:621-6
6. Staessen JA, Gasowski J, Wang JG, et al.
Risks of untreated and treated isolated
systolic hypertension in the elderly:
meta-analysis of outcome trials. Lancet
2000;355:865-72
7. Treatment of mild hypertension in the
elderly. A study initiated and
administered by the National Heart
Foundation of Australia. Med J Aust
1981;2:398-402
8. Amery A, Birkenhager W, Brixko P,
et al. Mortality and morbidity results
from the European Working Party on
High Blood Pressure in the Elderly Trial.
Lancet 1985;1:1349-54
9. Coope J, Warrender TS. Randomised
trial of treatment of hypertension in
elderly patients in primary care.
Br Med J (Clin Res Ed)
1986;293:1145-51
10. Dahlof B, Lindholm LH, Hansson L,
et al. Morbidity and mortality in the
Swedish Trial in Old Patients with
Hypertension (STOP-Hypertension).
Lancet 1991;338:1281-5
11. Medical Research Council trial of
treatment of hypertension in older adults.
principal results. MRC Working Party.
BMJ 1992;304:405-12
12. Prevention of stroke by antihypertensive
drug treatment in older persons with
isolated systolic hypertension. Final
results of the Systolic Hypertension in
the Elderly Program (SHEP). SHEP
Cooperative Research Group. JAMA
1991;265:3255-64
13. Staessen JA, Fagard R, Thijs L, et al.
Randomised double-blind comparison of
placebo and active treatment for older
patients with isolated systolic
hypertension. The Systolic Hypertension
in Europe (Syst-Eur) Trial Investigators.
Lancet 1997;350:757-64
14. Forette F, Seux ML, Staessen JA, et al.
Prevention of dementia in randomised
double-blind placebo-controlled Systolic
Hypertension in Europe (Syst-Eur) trial.
Lancet 1998;352:1347-51
15. Liu L, Wang JG, Gong L, et al.
Comparison of active treatment and
placebo in older Chinese patients with
isolated systolic hypertension. Systolic
Hypertension in China (Syst-China)
Collaborative Group. J Hypertens
1998;16:1823-9
16. Wing LM, Reid CM, Ryan P, et al.
A comparison of outcomes with
angiotensin-converting-enzyme inhibitors
and diuretics for hypertension in the
elderly. N Engl J Med 2003;348:583-92
17. Lithell H, Hansson L, Skoog I, et al.
The Study on Cognition and Prognosis
in the Elderly (SCOPE): principal results
of a randomized double-blind
intervention trial. J Hypertens
2003;21:875-86
18. Kjeldsen SE, Dahlof B, Devereux RB,
et al. Effects of losartan on cardiovascular
morbidity and mortality in patients with
isolated systolic hypertension and left
ventricular hypertrophy: a Losartan
Intervention for Endpoint Reduction
(LIFE) substudy. JAMA
2002;288:1491-8
19. Malacco E, Mancia G, Rappelli A, et al.
Treatment of isolated systolic
hypertension: the SHELL study results.
Blood Press 2003;12:160-7
20. Mancia G, Ruilope L, Palmer C, et al.
Effects of nifedipine GITS and diuretics
in isolated systolic hypertension -- a
subanalysis of the INSIGHT study.
Blood Press 2004;13:310-15
21. Malacco E, Vari N, Capuano V, et al.
A randomized, double-blind,
active-controlled, parallel-group
comparison of valsartan and amlodipine
in the treatment of isolated systolic
hypertension in elderly patients: the
Val-Syst study. Clin Ther
2003;25:2765-80
22. London G, Schmieder R, Calvo C,
Asmar R. Indapamide SR versus
candesartan and amlodipine in
hypertension: the X-CELLENT Study.
Am J Hypertens 2006;19:113-21
23. Duprez DA, Munger MA, Botha J, et al.
Aliskiren for Geriatric Lowering of
Systolic Hypertension: a randomized
controlled trial. J Hum Hypertens
2009: published online
24 December 2009,
doi:10.1038/jhh.2009.107
24. Gueyffier F, Bulpitt C, Boissel JP, et al.
Antihypertensive drugs in very old
people: a subgroup meta-analysis of
randomised controlled trials.
INDANA Group. Lancet
1999;353:793-6
25. Beckett NS, Peters R, Fletcher AE, et al.
Treatment of hypertension in patients
80 years of age or older. N Engl J Med
2008;358:1887-98
26. Musini VM, Tejani AM, Bassett K,
Wright JM. Pharmacotherapy for
hypertension in the elderly.
Cochrane Database Syst Rev
2010;1:793-6
27. Jamerson K, Weber MA, Bakris GL,
et al. Benazepril plus amlodipine or
hydrochlorothiazide for hypertension in
high-risk patients. N Engl J Med
2008;359:2417-28
28. Major outcomes in high-risk hypertensive
patients randomized to
angiotensin-converting enzyme inhibitor
or calcium channel blocker vs diuretic.
the Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial
(ALLHAT). JAMA 2002;288:2981-97
29. Mortality after 10 1/2 years for
hypertensive participants in the Multiple
Risk Factor Intervention Trial.
Circulation 1990;82:1616-28
30. Angeli F, Verdecchia P, Reboldi GP,
et al. Calcium channel blockade to
prevent stroke in hypertension:
a meta-analysis of 13 studies with
103,793 subjects. Am J Hypertens
2004;17:817-22
31. Turnbull F, Neal B, Ninomiya T, et al.
Effects of different regimens to lower
blood pressure on major cardiovascular
Hypertension in the elderly
S8 Expert Opin. Pharmacother. (2010) 11(Suppl.1)
Ex
pe
rt 
O
pi
n.
 P
ha
rm
ac
ot
he
r. 
D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
19
5.
15
0.
23
2.
34
 o
n 
05
/1
7/
10
Fo
r p
er
so
na
l u
se
 o
nl
y.
events in older and younger adults:
meta-analysis of randomised trials. BMJ
2008;336:1121-3
32. Rutan GH, Hermanson B, Bild DE,
et al. Orthostatic hypotension in older
adults. The Cardiovascular Health Study.
CHS Collaborative Research Group.
Hypertension 1992;19:508-19
33. Birkenhager WH, Forette F, Seux ML,
et al. Blood pressure, cognitive functions,
and prevention of dementias in older
patients with hypertension.
Arch Intern Med 2001;161:152-6
34. Mancia G, De Backer G, Dominiczak A,
et al. 2007 ESH-ESC Practice Guidelines
for the Management of Arterial
Hypertension: ESH-ESC Task Force on
the Management of Arterial
Hypertension. J Hypertens
2007;25:1751-62
35. Port S, Demer L, Jennrich R, et al.
Systolic blood pressure and mortality.
Lancet 2000;355:175-80
36. Mancia G, Laurent S, Agabiti-Rosei E,
et al. Reappraisal of European guidelines
on hypertension management:
a European Society of Hypertension Task
Force document. Blood Press
2009;18:308-47
37. Zanchetti A, Grassi G, Mancia G. When
should antihypertensive drug treatment
be initiated and to what levels should
systolic blood pressure be lowered?
A critical reappraisal. J Hypertens
2009;27:923-34
38. JATOS Study Group. Principal results of
the Japanese trial to assess optimal
systolic blood pressure in elderly
hypertensive patients (JATOS).
Hypertens Res 2008;31:2115-27
39. Bakris GL, Gaxiola E, Messerli FH, et al.
Clinical outcomes in the diabetes cohort
of the INternational VErapamil
SR-Trandolapril study. Hypertension
2004;44:637-42
Affiliation
Jerzy Ga˛sowski†1 MD PhD, Vale´rie Tikhonoff2,
Katarzyna Stolarz-Skrzypek3,4, Lutgarde Thijs4,
Tomasz Grodzicki1, Kalina Kawecka-Jaszcz3 &
Jan A Staessen4,5
†Author for correspondence
1Jagiellonian University,
Department of Internal Medicine and
Gerontology,
10 S´niadeckich St, 31-537 Krako´w, Poland
Tel: +48 12 424 8800; Fax: +48 12 424 8854;
E-mail: jerzy.gasowski@wp.pl
2University of Padova,
Department of Clinical and Experimental
Medicine,
Padova, Italy
3Jagiellonian University,
First Department of Cardiology and
Hypertension,
Krako´w, Poland
4University of Leuven,
Studies Coordinating Centre,
Division of Hypertension and Cardiovascular
Rehabilitation,
Department of Cardiovascular Research,
Leuven, Belgium
5Maastricht University,
Department of Epidemiology,
Maastricht, The Netherlands
Ga˛sowski, Tikhonoff, Stolarz-Skrzypek, Thijs, Grodzicki, Kawecka-Jaszcz & Staessen
Expert Opin. Pharmacother. (2010) 11(Suppl.1) S9
Ex
pe
rt 
O
pi
n.
 P
ha
rm
ac
ot
he
r. 
D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
19
5.
15
0.
23
2.
34
 o
n 
05
/1
7/
10
Fo
r p
er
so
na
l u
se
 o
nl
y.
